Trump Cannabis Order Triggers Industry Rally Across MSO Stocks
Executive action on federal rescheduling sends multi-state operators surging as investors price in regulatory shift potential
Multi-state cannabis operators experienced immediate trading gains following reports of executive action on federal rescheduling, with several MSO stocks posting double-digit percentage increases in early trading. The market response reflects investor anticipation that administrative changes could accelerate the rescheduling process that has remained stalled since the DEA's initial review period began in 2022.
The executive order represents the first concrete federal cannabis policy action of the new administration, potentially expediting the transition from Schedule I to Schedule III classification that would fundamentally alter the industry's tax burden. Under current 280E restrictions, cannabis companies cannot deduct standard business expenses, creating effective tax rates exceeding 70% for profitable operators like Green Thumb Industries and Trulieve Cannabis.
Rescheduling to Schedule III would eliminate 280E penalties, potentially increasing EBITDA margins by 15-25 percentage points across the sector. This tax relief becomes particularly valuable as MSOs face compressed margins from state-level price competition and oversupply conditions in mature markets like California and Colorado. Companies with strong operational efficiency, including Curaleaf and Cresco Labs, stand to benefit most from the improved unit economics.
The timing coincides with growing state-level momentum, as Ohio and Minnesota prepare to launch adult-use programs while Florida considers expanding its medical framework. This creates a dual catalyst environment where federal tax relief could amplify revenue growth from new market entries. However, rescheduling maintains federal prohibition on interstate commerce, preserving the fragmented state-by-state operating model that has defined the industry.
Investor focus now shifts to implementation timeline and scope, as the rescheduling process requires DEA administrative procedures that typically span 12-18 months. The executive order signals political prioritization but cannot bypass the regulatory review requirements that have delayed previous attempts at classification changes. Market participants will monitor whether this administrative push translates into accelerated DEA action or faces the same bureaucratic delays that have characterized federal cannabis policy.